# A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

> **NCT03006926** · PHASE1 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 104 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** lenvatinib
- **DRUG:** pembrolizumab (200 mg)

## Key facts

- **NCT ID:** NCT03006926
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-13
- **Primary completion:** 2019-10-31
- **Final completion:** 2022-11-22
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2023-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006926, "A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03006926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*